Apollo & RMS REGROW bring to India first of its kind innovative cell therapy treatment for Orthopedic Patients

  • Apollo Hospitals ties up with RMS Regrow exclusively to offer cell therapy for cartilage and bone problems
  • OssronTM for bone treatment is first in the world & Chondron® for cartilage treatment is the first in India and third  in the world



New Delhi, June 19, 2017: Apollo Hospitals, Asia’s largest and most trusted healthcare group, has partnered with RMS REGROW, the first ‘Make in India’ Company in Cell Therapy Technology, to offer two new Regenerative Medicine Cell Therapy products- Ossron™ and Chondron® for bone and cartilage problems, respectively. The two products will address unmet clinical needs in the orthopaedic market with respect to sports injuries, accidents and alternate to hip replacements and knee replacements for a young arthritic knee. In an exclusive tie up between Apollo Hospitals and RMS Regrow, the treatment therapy will be made available across all Apollo Hospitals, Apollo Spectra Hospitals and Apollo clinics in India.

Ossron™ and Chondron® are the results of a dedicated research team at REGROW. The two products are innovative proprietary and patented technology which has been developed for both the products following the regulatory guidelines. Through several clinical trials and evaluation studies over 8 years, the company has achieved the market authorization for the two cell therapy products.

As an exclusive offering, Apollo Hospitals will create a platform for orthopaedic doctors to practice Regenerative Medicine efficiently by conducting live surgical workshops, CME’s for doctors and conferences (national and international).

Speaking on the occasion, Dr Prathap C Reddy, Founder-Chairman of Apollo Hospitals, said: “Bringing innovation in healthcare and addressing the unmet medical needs of India has been the foremost aim of the Apollo Group. In our quest to do so, we also want to encourage research and innovation within India for the people of India. Our association with RMS Regrow is a step to inspire talent in India to further the advancement in developing innovative healthcare treatments to reduce the growing disease burden in India.”

Commenting on the launch Mr Yash Sanghavi, Founder and CEO of RMS REGROW, “We are delighted to partner with a leader like Apollo Hospitals which offers RMS REGROW unprecedented opportunity to reach patients pan India. It has taken 8 years of dedicated effort and innovative research to develop the two revolutionary products that will change the modalities for bone and cartilage treatment in India. Since last 70 years, only a handful of  New Chemical Entities (NCE) have been developed in India, which demonstrates a dearth of innovator drugs and new medical technologies to address a large market of bone and joint disorders. In India, more than 15 lac (>15, 00,000) orthopaedic procedures are performed each year and Regenerative Cell Therapy is a revolutionary treatment methodology which has immense potential to liberate consumers from Joint pain.”


Also present on the occasion was Ms Sangita Reddy, Joint Managing Director, Apollo Hospitals. Commenting on the development, she says “At Apollo Hospitals, bringing innovative treatments to improve the quality of life of our patients is paramount. We have also developed the expertise to create ecosystems that enable use of the developing health technology. These two products are revolutionary and Apollo’s doctors in partnership with RMS REGROW, will develop workshops and educative sessions across India to bring this technology to practice at the earliest.”



It was in 1983, that Dr. Prathap Reddy made a pioneering endeavour by launching India’s first corporate hospital – Apollo Hospitals in Chennai. Over the years Apollo Hospitals has established itself as home to the largest cardiac practice in India with over 160,000 cardiac surgeries. Apollo Hospitals is also the world’s largest private cancer care provider and runs the world’s leading solid organ transplant program.


As Asia’s largest and most trusted healthcare group, its presence includes 9,215 beds across 64 Hospitals, 2,500 Pharmacies, over 90 Primary Care and Diagnostic Clinics, 110  plus Telemedicine Centres and 80 plus Apollo Munich Insurance branches spanning the length and breadth of the Country. 


As an integrated healthcare service provider with Health Insurance services, Global Projects Consultancy capability, over 15 medical education centres and a Research Foundation with a focus on global Clinical Trials, epidemiological studies, stem cell & genetic research Apollo Hospitals has been at the forefront of new medical breakthroughs with the most recent investment being that of commissioning the first Proton Therapy Center across Asia, Africa and Australia in Chennai, India. Every four days, the Apollo Hospitals Group touches a million lives, in its mission to bring healthcare of International standards within the reach of every individual.


In a rare honour, the Government of India issued a commemorative stamp in recognition of Apollo’s contribution, the first for a healthcare organization. Apollo Hospitals Chairman, Dr. Prathap C Reddy, was conferred with the prestigious Padma Vibhushan in 2010. For more than 30 years, the Apollo Hospitals Group has continuously excelled and maintained leadership in medical innovation, world-class clinical services and cutting-edge technology. Our hospitals are consistently ranked amongst the best hospitals globally for advanced medical services and research.



Regenerative Medical Services Pvt. Ltd. is the first Indian Biotechnology Company established in the year 2009 to introduce cutting edge technology platform for regenerative medicine in India.

Vision of Regenerative Medical Services Pvt. Ltd. is to contribute in improving human healthcare by delivering safe and effective patient specific regenerative medical treatment.


The aim of regenerative medicine is to replace, repair or enhance the function of damaged tissue or organs by accelerating and securing natural process with autologous cell therapy via minimally invasive techniques without side effects.


The company headquartered is in Mumbai, India and has a best in class Cell Processing Centre (CPC)TM at Lonavala and has been awarded and certified with GMP & GLP. The Quality Management System is also certified by ISO 13485:2003 by the British Standards Institute, UK.